Overview Epidemiology Thyroid nodules are approximately 4 times more common in women than in men. Palpable nodules increase in frequency throughout life, reaching a prevalence of approximately 5% in the United States population aged 50 years and older.1–3 Nodules are even more prevalent when the thyroid gland is examined at autopsy or surgery, or when using ultrasonography, and 50% of these have nodules, which are almost always benign.2,4 New nodules develop at a rate of approximately 0.1% per year beginning in early life, but at a much higher rate (∼2% per year) after exposure to head and neck irradiation.5,6 By contrast, thyroid carcinoma is uncommon. For the United States population, the lifetime risk of being diagnosed with thyroid carcinoma is less than 1% (0.83% for women and 0.33% for men).7 Approximately 37,200 new cases of thyroid carcinoma were diagnosed in the United States in 2009.8 As with thyroid nodules, thyroid carcinoma occurs 2 to 3 times more often in women than in men. With the incidence increasing by 6.2% per year, thyroid carcinoma is currently the sixth most common malignancy diagnosed in women.8 Among persons age 15 to 24 years, thyroid carcinoma accounts for 7.5% to 10% of all diagnosed malignancies.9–11 The disease is also diagnosed more often in white North Americans than in African Americans. Although thyroid carcinoma can occur at any age, the peak incidence from 2004 to 2006 was near age 45 to 49 years in women and 65 to 69 years in men.7 Thyroid carcinoma has...
  • 1.

    Mazzaferri EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferri EL, Samaan N, eds. Endocrine Tumors. Cambridge, United Kingdom: Blackwell Scientific Publications; 1993:278333.

    • Search Google Scholar
    • Export Citation
  • 2.

    Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004;351:17641771.

  • 3.

    Cooper DS, Doherty GM, Haugen BR. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109142.

    • Search Google Scholar
    • Export Citation
  • 4.

    Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med 1994;154:18381840.

    • Search Google Scholar
    • Export Citation
  • 5.

    Ron E, Lubin JH, Shore RE. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259277.

    • Search Google Scholar
    • Export Citation
  • 6.

    Schneider AB, Bekerman C, Leland J. Thyroid nodules in the follow-up of irradiated individuals: comparison of thyroid ultrasound with scanning and palpation. J Clin Endocrinol Metab 1997;82:40204027.

    • Search Google Scholar
    • Export Citation
  • 7.

    Horner MJ, Ries LAG, Krapcho M., eds. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009. Accessed October 6, 2010.

    • Search Google Scholar
    • Export Citation
  • 8.

    Jemal A, Siegel R, Ward E. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225249.

  • 9.

    Wu XC, Chen VW, Steele B. Cancer incidence in adolescents and young adults in the United States, 1992–1997. J Adolesc Health 2003;32:405415.

    • Search Google Scholar
    • Export Citation
  • 10.

    Wu X, Groves FD, McLaughlin CC. Cancer incidence patterns among adolescents and young adults in the United States. Cancer Causes Control 2005;16:309320.

    • Search Google Scholar
    • Export Citation
  • 11.

    Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist 2006;11:590601.

  • 12.

    Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer 1998;83:26382648.

    • Search Google Scholar
    • Export Citation
  • 13.

    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418428.

    • Search Google Scholar
    • Export Citation
  • 14.

    Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006;295:21642167.

  • 15.

    Ito Y, Tomoda C, Uruno T. Papillary microcarcinoma of the thyroid: how should it be treated? World J Surg 2004;28:11151121.

  • 16.

    Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009;115:38013807.

    • Search Google Scholar
    • Export Citation
  • 17.

    Enewold L, Zhu K, Ron E. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 2009;18:784791.

    • Search Google Scholar
    • Export Citation
  • 18.

    Sherman SI. Thyroid carcinoma. Lancet 2003;361:501511.

  • 19.

    Wong FL, Ron E, Gierlowski T, Schneider AB. Benign thyroid tumors: general risk factors and their effects on radiation risk estimation. Am J Epidemiol 1996;144:728733.

    • Search Google Scholar
    • Export Citation
  • 20.

    Ron E, Doody MM, Becker DV. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 1998;280:347355.

    • Search Google Scholar
    • Export Citation
  • 21.

    Jacob P, Goulko G, Heidenreich WF. Thyroid cancer risk to children calculated. Nature 1998;392:3132.

  • 22.

    Schneider AB. Radiation-induced thyroid tumors. Endocrinol Metab Clin North Am 1990;19:495508.

  • 23.

    Nikiforov YE, Nikiforova M, Fagin JA. Prevalence of minisatellite and microsatellite instability in radiation-induced post-Chernobyl pediatric thyroid carcinomas. Oncogene 1998;17:19831988.

    • Search Google Scholar
    • Export Citation
  • 24.

    Kaplan MM. Clinical evaluation and management of solitary thyroid nodules. In: Braverman LE, Utiger RD, eds. Werner and Ingbar's The Thyroid: A Fundamental and Clinical Text, 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:9961010.

    • Search Google Scholar
    • Export Citation
  • 25.

    Layfield LJ, Cibas ES, Gharib H, Mandel SJ. Thyroid aspiration cytology: current status. CA Cancer J Clin 2009;59:99110.

  • 26.

    Ito Y, Uruno T, Nakano K. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13:381387.

    • Search Google Scholar
    • Export Citation
  • 27.

    Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997;126:226231.

    • Search Google Scholar
    • Export Citation
  • 28.

    Frates MC, Benson CB, Charboneau JW. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005;237:794800.

    • Search Google Scholar
    • Export Citation
  • 29.

    Mazzaferri EL. Thyroid cancer in thyroid nodules: finding a needle in the haystack. Am J Med 1992;93:359362.

  • 30.

    Hamming JF, Goslings BM, van Steenis GJ. The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. Arch Intern Med 1990;150:113116.

    • Search Google Scholar
    • Export Citation
  • 31.

    Chan BK, Desser TS, McDougall IR. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med 2003;22:10831090.

    • Search Google Scholar
    • Export Citation
  • 32.

    Haymart MR, Repplinger DJ, Leverson GE. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008;93:809814.

    • Search Google Scholar
    • Export Citation
  • 33.

    Henry JF, Denizot A, Puccini M. [Early diagnosis of sporadic medullary cancers of the thyroid: value of systematic assay of calcitonin]. Presse Med 1996;25:15831588 [in French].

    • Search Google Scholar
    • Export Citation
  • 34.

    Cooper DS, Doherty GM, Haugen BR. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:11671214.

    • Search Google Scholar
    • Export Citation
  • 35.

    Cheung K, Roman SA, Wang TS. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab 2008;93:21732180.

    • Search Google Scholar
    • Export Citation
  • 36.

    Koike E, Noguchi S, Yamashita H. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 2001;136:334337.

  • 37.

    Baloch ZW, Cibas ES, Clark DP. The National Cancer Institute thyroid fine needle aspiration state of the science conference: a summation. Cytojournal 2008;5:6.

    • Search Google Scholar
    • Export Citation
  • 38.

    Yeh MW, Demircan O, Ituarte P, Clark OH. False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. Thyroid 2004;14:207215.

    • Search Google Scholar
    • Export Citation
  • 39.

    Asa SL, Bedard YC. Fine-needle aspiration cytology and histopathology. In: Clark OH, Noguchi S, eds. Thyroid Cancer: Diagnosis and Treatment. St Louis, MO: Quality Medical Publishing; 2000:105126.

    • Search Google Scholar
    • Export Citation
  • 40.

    Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK. Diagnosis of ``follicular neoplasm'': a gray zone in thyroid fine-needle aspiration cytology. Diagn Cytopathol 2002;26:4144.

    • Search Google Scholar
    • Export Citation
  • 41.

    Cersosimo E, Gharib H, Suman VJ, Goellner JR. ``Suspicious'' thyroid cytologic findings: outcome in patients without immediate surgical treatment. Mayo Clin Proc 1993;68:343348.

    • Search Google Scholar
    • Export Citation
  • 42.

    McHenry CR, Walfish PG, Rosen IB. Non-diagnostic fine needle aspiration biopsy: a dilemma in management of nodular thyroid disease. Am Surg 1993;59:415419.

    • Search Google Scholar
    • Export Citation
  • 43.

    Newman KD, Black T, Heller G. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group. Ann Surg 1998;227:533541.

    • Search Google Scholar
    • Export Citation
  • 44.

    Robie DK, Dinauer CW, Tuttle RM. The impact of initial surgical management on outcome in young patients with differentiated thyroid cancer. J Pediatr Surg 1998;33:11341138; discussion 1139–1140.

    • Search Google Scholar
    • Export Citation
  • 45.

    Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer 1997;79:564573.

    • Search Google Scholar
    • Export Citation
  • 46.

    Sherman SI, Brierley JD, Sperling M. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:10121021.

    • Search Google Scholar
    • Export Citation
  • 47.

    Tsang RW, Brierley JD, Simpson WJ. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998;82:375388.

    • Search Google Scholar
    • Export Citation
  • 48.

    Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553559.

  • 49.

    Dottorini ME, Vignati A, Mazzucchelli L. Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 1997;38:669675.

    • Search Google Scholar
    • Export Citation
  • 50.

    Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998;39:15311536.

    • Search Google Scholar
    • Export Citation
  • 51.

    Schlumberger M, De Vathaire F, Travagli JP. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987;65:10881094.

    • Search Google Scholar
    • Export Citation
  • 52.

    Hay ID, Bergstralh EJ, Goellner JR. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 1993;114:10501057; discussion 1057–1058.

    • Search Google Scholar
    • Export Citation
  • 53.

    Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118:11311136; discussion 1136–1138.

    • Search Google Scholar
    • Export Citation
  • 54.

    Cady B. Staging in thyroid carcinoma. Cancer 1998;83:844847.

  • 55.

    DeGroot LJ, Kaplan EL, Straus FH, Shukla MS. Does the method of management of papillary thyroid carcinoma make a difference in outcome? World J Surg 1994;18:123130.

    • Search Google Scholar
    • Export Citation
  • 56.

    Miccoli P, Antonelli A, Spinelli C. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg 1998;133:8993.

    • Search Google Scholar
    • Export Citation
  • 57.

    Palme CE, Waseem Z, Raza SN. Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:819824.

    • Search Google Scholar
    • Export Citation
  • 58.

    Frankenthaler RA, Sellin RV, Cangir A, Goepfert H. Lymph node metastasis from papillary-follicular thyroid carcinoma in young patients. Am J Surg 1990;160:341343.

    • Search Google Scholar
    • Export Citation
  • 59.

    Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 2005;90:57475753.

  • 60.

    Agostini L, Mazzi P, Cavaliere A. Multiple primary malignant tumours: gemistocytic astrocytoma with leptomeningeal spreading and papillary thyroid carcinoma. A case report. Acta Neurol (Napoli) 1990;12:305310.

    • Search Google Scholar
    • Export Citation
  • 61.

    Soravia C, Sugg SL, Berk T. Familial adenomatous polyposis-associated thyroid cancer: a clinical, pathological, and molecular genetics study. Am J Pathol 1999;154:127135.

    • Search Google Scholar
    • Export Citation
  • 62.

    Stratakis CA, Courcoutsakis NA, Abati A. Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex). J Clin Endocrinol Metab 1997;82:20372043.

    • Search Google Scholar
    • Export Citation
  • 63.

    Marsh DJ, Dahia PL, Caron S. Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 1998;35:881885.

  • 64.

    Mazzaferri EL. Papillary thyroid carcinoma: factors influencing prognosis and current therapy. Semin Oncol 1987;14:315332.

  • 65.

    LiVolsi VA. Follicular lesions of the thyroid. In: LiVolsi VA, ed. Surgical Pathology of the Thyroid. Philadelphia, PA: WB Saunders; 1990:173212.

    • Search Google Scholar
    • Export Citation
  • 66.

    LiVolsi VA. Papillary lesions of the thyroid. In: LiVolsi VA, ed. Surgical Pathology of the Thyroid. Philadelphia, PA: WB Saunders; 1990:136172.

    • Search Google Scholar
    • Export Citation
  • 67.

    LiVolsi VA. Unusual variants of papillary thyroid carcinoma. In: Mazzaferri EL, Kreisberg RA, Bar RS, eds. Advances in Endocrinology and Metabolism. St. Louis, MO: Mosby-Year Book; 1994:3954.

    • Search Google Scholar
    • Export Citation
  • 68.

    Tielens ET, Sherman SI, Hruban RH, Ladenson PW. Follicular variant of papillary thyroid carcinoma. A clinicopathologic study. Cancer 1994;73:424431.

    • Search Google Scholar
    • Export Citation
  • 69.

    Liu J, Singh B, Tallini G. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006;107:12551264.

    • Search Google Scholar
    • Export Citation
  • 70.

    van Heerden JA, Hay ID, Goellner JR. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 1992;112:11301136; discussion 1136–1138.

    • Search Google Scholar
    • Export Citation
  • 71.

    LiVolsi VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. Thyroid 1994;4:233236.

  • 72.

    Brennan MD, Bergstralh EJ, van Heerden JA, McConahey WM. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991;66:1122.

    • Search Google Scholar
    • Export Citation
  • 73.

    Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual, 6th ed. New York, NY: Springer-Verlag; 2002.

  • 74.

    Edge SB, Byrd DR, Compton CC, eds. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

  • 75.

    Fleming ID, Cooper JS, Henson DE. AJCC Cancer Staging Manual, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1997.

  • 76.

    Hedinger CE. [Problems in the classification of thyroid tumors. Their significance for prognosis and therapy]. Schweiz Med Wochenschr 1993;123:16731681 [in German].

    • Search Google Scholar
    • Export Citation
  • 77.

    Belchetz G, Cheung CC, Freeman J. Hurthle cell tumors: using molecular techniques to define a novel classification system. Arch Otolaryngol Head Neck Surg 2002;128:237240.

    • Search Google Scholar
    • Export Citation
  • 78.

    Chen H, Nicol TL, Zeiger MA. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 1998;227:542546.

  • 79.

    Thompson NW, Dunn EL, Batsakis JG, Nishiyama RH. Hurthle cell lesions of the thyroid gland. Surg Gynecol Obstet 1974;139:555560.

  • 80.

    Lopez-Penabad L, Chiu AC, Hoff AO. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 2003;97:11861194.

  • 81.

    Khafif A, Khafif RA, Attie JN. Hurthle cell carcinoma: a malignancy of low-grade potential. Head Neck 1999;21:506511.

  • 82.

    Ruegemer JJ, Hay ID, Bergstralh EJ. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501508.

    • Search Google Scholar
    • Export Citation
  • 83.

    Samaan NA, Schultz PN, Hickey RC. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714720.

    • Search Google Scholar
    • Export Citation
  • 84.

    Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985;60:376380.

    • Search Google Scholar
    • Export Citation
  • 85.

    Baudin E, Travagli JP, Ropers J. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998;83:553559.

  • 86.

    Sugino K, Ito K Jr, Ozaki O. Papillary microcarcinoma of the thyroid. J Endocrinol Invest 1998;21:445448.

  • 87.

    Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am 1990;19:545576.

  • 88.

    Emerick GT, Duh QY, Siperstein AE. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 1993;72:32873295.

  • 89.

    Salvesen H, Njolstad PR, Akslen LA. Papillary thyroid carcinoma: a multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur J Surg 1992;158:583589.

    • Search Google Scholar
    • Export Citation
  • 90.

    Pingpank JF Jr, Sasson AR, Hanlon AL. Tumor above the spinal accessory nerve in papillary thyroid cancer that involves lateral neck nodes: a common occurrence. Arch Otolaryngol Head Neck Surg 2002;128:12751278.

    • Search Google Scholar
    • Export Citation
  • 91.

    Yamashita H, Noguchi S, Murakami N. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 1997;80:22682272.

    • Search Google Scholar
    • Export Citation
  • 92.

    Sellers M, Beenken S, Blankenship A. Prognostic significance of cervical lymph node metastases in differentiated thyroid cancer. Am J Surg 1992;164:578581.

    • Search Google Scholar
    • Export Citation
  • 93.

    Lindegaard MW, Paus E, Hoie J. Thyroglobulin radioimmunoassay and 131I scintigraphy in patients with differentiated thyroid carcinoma. Acta Chir Scand 1988;154:141145.

    • Search Google Scholar
    • Export Citation
  • 94.

    Schlumberger M, Challeton C, De Vathaire F, Parmentier C. Treatment of distant metastases of differentiated thyroid carcinoma. J Endocrinol Invest 1995;18:170172.

    • Search Google Scholar
    • Export Citation
  • 95.

    Sisson JC, Giordano TJ, Jamadar DA. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 1996;78:21842192.

    • Search Google Scholar
    • Export Citation
  • 96.

    Brown AP, Greening WP, McCready VR. Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience. Br J Radiol 1984;57:323327.

    • Search Google Scholar
    • Export Citation
  • 97.

    Casara D, Rubello D, Saladini G. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993;34:16261631.

    • Search Google Scholar
    • Export Citation
  • 98.

    Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997;174:462468.

    • Search Google Scholar
    • Export Citation
  • 99.

    Cady B, Sedgwick CE, Meissner WA. Risk factor analysis in differentiated thyroid cancer. Cancer 1979;43:810820.

  • 100.

    Loh KC, Greenspan FS, Gee L. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:35533562.

    • Search Google Scholar
    • Export Citation
  • 101.

    Lin JD, Kao PF, Weng HF. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma. Eur J Nucl Med 1998;25:695700.

    • Search Google Scholar
    • Export Citation
  • 102.

    Brierley JD, Panzarella T, Tsang RW. A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. Cancer 1997;79:24142423.

    • Search Google Scholar
    • Export Citation
  • 103.

    Sherman SI. Toward a standard clinicopathologic staging approach for differentiated thyroid carcinoma. Semin Surg Oncol 1999;16:1215.

  • 104.

    Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:10881095.

    • Search Google Scholar
    • Export Citation
  • 105.

    Hay ID, Grant CS, Bergstralh EJ. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124:958964.

    • Search Google Scholar
    • Export Citation
  • 106.

    Dackiw AP, Zeiger M. Extent of surgery for differentiated thyroid cancer. Surg Clin North Am 2004;84:817832.

  • 107.

    Mazzaferri EL. Treating differentiated thyroid carcinoma: where do we draw the line? Mayo Clin Proc 1991;66:105111.

  • 108.

    Massin JP, Savoie JC, Garnier H. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984;53:982992.

    • Search Google Scholar
    • Export Citation
  • 109.

    Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004;114:393402.

    • Search Google Scholar
    • Export Citation
  • 110.

    DeGroot LJ, Kaplan EL. Second operations for ``completion'' of thyroidectomy in treatment of differentiated thyroid cancer. Surgery 1991;110:936939; discussion 939–940.

    • Search Google Scholar
    • Export Citation
  • 111.

    Pasieka JL, Thompson NW, McLeod MK. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg 1992;16:711716; discussion 716–717.

    • Search Google Scholar
    • Export Citation
  • 112.

    Scheumann GF, Seeliger H, Musholt TJ. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg 1996;162:677684.

    • Search Google Scholar
    • Export Citation
  • 113.

    Chao TC, Jeng LB, Lin JD, Chen MF. Completion thyroidectomy for differentiated thyroid carcinoma. Otolaryngol Head Neck Surg 1998;118:896899.

  • 114.

    Pacini F, Elisei R, Capezzone M. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid 2001;11:877881.

    • Search Google Scholar
    • Export Citation
  • 115.

    Burge MR, Zeise TM, Johnsen MW. Risks of complication following thyroidectomy. J Gen Intern Med 1998;13:2431.

  • 116.

    Dralle H, Gimm O, Simon D. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998;22:744750.

    • Search Google Scholar
    • Export Citation
  • 117.

    Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:8893.

  • 118.

    Pattou F, Combemale F, Fabre S. Hypocalcemia following thyroid surgery: incidence and prediction of outcome. World J Surg 1998;22:718724.

  • 119.

    Sosa JA, Bowman HM, Tielsch JM. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320330.

    • Search Google Scholar
    • Export Citation
  • 120.

    Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:14471463.

    • Search Google Scholar
    • Export Citation
  • 121.

    Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 1997;7:265271.

  • 122.

    Taylor T, Specker B, Robbins J. Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 1998;129:622627.

    • Search Google Scholar
    • Export Citation
  • 123.

    Robbins RJ, Schlumberger MJ. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 2005;46(Suppl 1):28S37S.

    • Search Google Scholar
    • Export Citation
  • 124.

    Leger FA, Izembart M, Dagousset F. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998;25:242246.

    • Search Google Scholar
    • Export Citation
  • 125.

    Muratet JP, Giraud P, Daver A. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. J Nucl Med 1997;38:13621368.

    • Search Google Scholar
    • Export Citation
  • 126.

    Mazzaferri EL. Carcinoma of follicular epithelium: Radioiodine and other treatment outcomes. In: Braverman LE, Utiger RD, eds. The Thyroid: A Fundamental and Clinical Text. Philadelphia, PA: Lippincott-Raven; 1996:922945.

    • Search Google Scholar
    • Export Citation
  • 127.

    Amdur RJ, Mazzaferri EL. Essentials of Thyroid Cancer Management. New York, NY: Springer Science; 2005.

  • 128.

    Brierley J, Maxon HR. Radioiodine and external radiation therapy in the treatment of thyroid cancer. In: Fagin JA, ed. Thyroid Cancer. Boston, MA: Kluwer Academic; 1998:285317.

    • Search Google Scholar
    • Export Citation
  • 129.

    Tuttle RM, Leboeuf R, Robbins RJ. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006;47:15871591.

    • Search Google Scholar
    • Export Citation
  • 130.

    Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 2007;36:807822, vii–viii.

  • 131.

    Maxon HR III, Englaro EE, Thomas SR. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med 1992;33:11321136.

    • Search Google Scholar
    • Export Citation
  • 132.

    Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171182.

    • Search Google Scholar
    • Export Citation
  • 133.

    Sherman SI, Tielens ET, Sostre S. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629634.

    • Search Google Scholar
    • Export Citation
  • 134.

    Pacini F, Molinaro E, Castagna MG. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:36683673.

    • Search Google Scholar
    • Export Citation
  • 135.

    Pacini F, Lari R, Mazzeo S. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 1985;23:405411.

    • Search Google Scholar
    • Export Citation
  • 136.

    Haugen BR, Pacini F, Reiners C. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999;84:38773885.

    • Search Google Scholar
    • Export Citation
  • 137.

    Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005;90:50475057.

    • Search Google Scholar
    • Export Citation
  • 138.

    Ladenson PW, Braverman LE, Mazzaferri EL. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888896.

    • Search Google Scholar
    • Export Citation
  • 139.

    Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:14901498.

    • Search Google Scholar
    • Export Citation
  • 140.

    Castagna MG, Brilli L, Pilli T. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 2008;93:7681.

    • Search Google Scholar
    • Export Citation
  • 141.

    Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyroglobulin assays. Clin Chem 1996;42:164173.

  • 142.

    Spencer CA, Lopresti JS. Measuring thyroglobulin and thyroglobulin autoantibody in patients with differentiated thyroid cancer. Nat Clin Pract Endocrinol Metab 2008;4:223233.

    • Search Google Scholar
    • Export Citation
  • 143.

    Spencer CA, Takeuchi M, Kazarosyan M. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83:11211127.

    • Search Google Scholar
    • Export Citation
  • 144.

    Chung JK, Park YJ, Kim TY. Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 2002;57:215221.

    • Search Google Scholar
    • Export Citation
  • 145.

    Chiovato L, Latrofa F, Braverman LE. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346351.

    • Search Google Scholar
    • Export Citation
  • 146.

    Milas M, Barbosa GF, Mitchell J. Effectiveness of peripheral thyrotropin receptor mRNA in follow-up of differentiated thyroid cancer. Ann Surg Oncol 2009;16:473480.

    • Search Google Scholar
    • Export Citation
  • 147.

    Barbosa GF, Milas M. Peripheral thyrotropin receptor mRNA as a novel marker for differentiated thyroid cancer diagnosis and surveillance. Expert Rev Anticancer Ther 2008;8:14151424.

    • Search Google Scholar
    • Export Citation
  • 148.

    Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998;83:44354442.

    • Search Google Scholar
    • Export Citation
  • 149.

    Ringel MD. Molecular detection of thyroid cancer: differentiating ``signal'' and ``noise'' in clinical assays. J Clin Endocrinol Metab 2004;89:2932.

    • Search Google Scholar
    • Export Citation
  • 150.

    Schlumberger M, Mancusi F, Baudin E, Pacini F. 131I therapy for elevated thyroglobulin levels. Thyroid 1997;7:273276.

  • 151.

    Schlumberger M, Tubiana M, De Vathaire F. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960967.

    • Search Google Scholar
    • Export Citation
  • 152.

    Pacini F, Lippi F, Formica N. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 1987;28:18881891.

    • Search Google Scholar
    • Export Citation
  • 153.

    Pineda JD, Lee T, Ain K. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 1995;80:14881492.

    • Search Google Scholar
    • Export Citation
  • 154.

    Mazzaferri EL. Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 1995;80:14851487.

    • Search Google Scholar
    • Export Citation
  • 155.

    Pacini F, Agate L, Elisei R. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131) I activities versus untreated patients. J Clin Endocrinol Metab 2001;86:40924097.

    • Search Google Scholar
    • Export Citation
  • 156.

    Burns JA, Morgenstern KE, Cahill KV. Nasolacrimal obstruction secondary to I(131) therapy. Ophthal Plast Reconstr Surg 2004;20:126129.

  • 157.

    McGriff NJ, Csako G, Gourgiotis L. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002;34:554564.

    • Search Google Scholar
    • Export Citation
  • 158.

    Pujol P, Daures JP, Nsakala N. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:43184323.

    • Search Google Scholar
    • Export Citation
  • 159.

    Cooper DS, Specker B, Ho M. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737744.

    • Search Google Scholar
    • Export Citation
  • 160.

    Burmeister LA, Goumaz MO, Mariash CN, Oppenheimer JH. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992;75:344350.

    • Search Google Scholar
    • Export Citation
  • 161.

    Jonklaas J, Sarlis NJ, Litofsky D. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16:12291242.

    • Search Google Scholar
    • Export Citation
  • 162.

    Biermann M, Pixberg MK, Schuck A. Multicenter study differentiated thyroid carcinoma (MSDS). Diminished acceptance of adjuvant external beam radiotherapy. Nuklearmedizin 2003;42:244250.

    • Search Google Scholar
    • Export Citation
  • 163.

    Farahati J, Reiners C, Stuschke M. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4). Cancer 1996;77:172180.

    • Search Google Scholar
    • Export Citation
  • 164.

    Simpson WJ, Panzarella T, Carruthers JS. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14:10631075.

    • Search Google Scholar
    • Export Citation
  • 165.

    Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:36373642.

    • Search Google Scholar
    • Export Citation
  • 166.

    Droz JP, Schlumberger M, Rougier P. Chemotherapy in metastatic nonanaplastic thyroid cancer: experience at the Institut Gustave-Roussy. Tumori 1990;76:480483.

    • Search Google Scholar
    • Export Citation
  • 167.

    Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987;10:303310.

  • 168.

    Mrozek E, Kloos RT, Ringel MD. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006;91:22012204.

    • Search Google Scholar
    • Export Citation
  • 169.

    Rosen LS, Kurzrock R, Mulay M. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007;25:23692376.

    • Search Google Scholar
    • Export Citation
  • 170.

    Sherman SI, Wirth LJ, Droz JP. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:3142.

  • 171.

    Kloos RT, Ringel MD, Knopp MV. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:16751684.

  • 172.

    Kloos R, Ringel M, Knopp M. Significant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II study [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 5534.

    • Search Google Scholar
    • Export Citation
  • 173.

    Gupta-Abramson V, Troxel AB, Nellore A. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:47144719.

  • 174.

    Cohen EE, Needles BM, Cullen KJ. Phase 2 study of sunitinib in refractory thyroid cancer [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 6025.

    • Search Google Scholar
    • Export Citation
  • 175.

    Goulart B, Carr L, Martins RG. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 6062.

    • Search Google Scholar
    • Export Citation
  • 176.

    Cohen EE, Rosen LS, Vokes EE. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:47084713.

    • Search Google Scholar
    • Export Citation
  • 177.

    Ain KB, Lee C, Holbrook KM. Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results [abstract]. J Clin Oncol 2008;26:Abstract 6027.

    • Search Google Scholar
    • Export Citation
  • 178.

    Deshpande HA, Gettinger SN, Sosa JA. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Curr Opin Oncol 2008;20:1924.

    • Search Google Scholar
    • Export Citation
  • 179.

    Tuttle RM, Leboeuf R. Investigational therapies for metastatic thyroid carcinoma. J Natl Compr Canc Netw 2007;5:641646.

  • 180.

    Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:713722.

  • 181.

    Kouvaraki MA, Shapiro SE, Fornage BD. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003;134:946954.

    • Search Google Scholar
    • Export Citation
  • 182.

    Moo TA, Umunna B, Kato M. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg 2009;250:403408.

    • Search Google Scholar
    • Export Citation
  • 183.

    Sadowski BM, Snyder SK, Lairmore TC. Routine bilateral central lymph node clearance for papillary thyroid cancer. Surgery 2009;146:696703.

  • 184.

    Palestini N, Borasi A, Cestino L. Is central neck dissection a safe procedure in the treatment of papillary thyroid cancer? Our experience. Langenbecks Arch Surg 2008;393:693698.

    • Search Google Scholar
    • Export Citation
  • 185.

    Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol 2005;12:8189.

    • Search Google Scholar
    • Export Citation
  • 186.

    Bilimoria KY, Bentrem DJ, Ko CY. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007;246:375381.

  • 187.

    Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. Thyroid 2003;13:333340.

  • 188.

    Eustatia-Rutten CF, Romijn JA, Guijt MJ. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:31843189.

    • Search Google Scholar
    • Export Citation
  • 189.

    Van Nostrand D, Atkins F, Yeganeh F. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 2002;12:121134.

    • Search Google Scholar
    • Export Citation
  • 190.

    Thompson LD, Wieneke JA, Paal E. A clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001;91:505524.

    • Search Google Scholar
    • Export Citation
  • 191.

    Sugino K, Ito K, Mimura T. Hurthle cell tumor of the thyroid: analysis of 188 cases. World J Surg 2001;25:11601163.

  • 192.

    Herrera MF, Hay ID, Wu PS. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg 1992;16:669674.

    • Search Google Scholar
    • Export Citation
  • 193.

    Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453464.

    • Search Google Scholar
    • Export Citation
  • 194.

    Kebebew E, Greenspan FS, Clark OH. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005;103:13301335.

  • 195.

    Moretti F, Farsetti A, Soddu S. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997;14:729740.

    • Search Google Scholar
    • Export Citation
  • 196.

    Sherman SI. Anaplastic carcinoma: clinical aspects. In: Wartofsky L, Van Nostrand D, eds. Thyroid Cancer: A Comprehensive Guide to Clinical Management, 2nd ed. Totowa, NJ: Humana Press; 2006:629632.

    • Search Google Scholar
    • Export Citation
  • 197.

    Takashima S, Morimoto S, Ikezoe J. CT evaluation of anaplastic thyroid carcinoma. AJR Am J Roentgenol 1990;154:10791085.

  • 198.

    Untch BR, Olson JA Jr. Anaplastic thyroid carcinoma, thyroid lymphoma, and metastasis to thyroid. Surg Oncol Clin N Am 2006;15:661679.

  • 199.

    Venkatesh YS, Ordonez NG, Schultz PN. Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases. Cancer 1990;66:321330.

  • 200.

    Junor EJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:8388.

  • 201.

    McIver B, Hay ID, Giuffrida DF. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:10281034.

  • 202.

    Wang Y, Tsang R, Asa S. Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006;107:17861792.

    • Search Google Scholar
    • Export Citation
  • 203.

    Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:23722375.

    • Search Google Scholar
    • Export Citation
  • 204.

    Wallin G, Lundell G, Tennvall J. Anaplastic giant cell thyroid carcinoma. Scand J Surg 2004;93:272277.

  • 205.

    Ain KB. Anaplastic thyroid carcinoma: behavior, biology, and therapeutic approaches. Thyroid 1998;8:715726.

  • 206.

    Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000;10:587594.

    • Search Google Scholar
    • Export Citation
  • 207.

    Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415427.

  • 208.

    Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009;16:1744.

    • Search Google Scholar
    • Export Citation
  • 209.

    Dowlati A, Robertson K, Cooney M. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:34083416.

    • Search Google Scholar
    • Export Citation
  • 210.

    Cooney MM, Savvides P, Agarwala S. Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC) [abstract]. J Clin Oncol 2006;24:Abstract 5580.

    • Search Google Scholar
    • Export Citation
  • 211.

    Mooney CJ, Nagaiah G, Fu P. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009;19:233240.

    • Search Google Scholar
    • Export Citation
  • 212.

    Heron DE, Karimpour S, Grigsby PW. Anaplastic thyroid carcinoma: comparison of conventional radiotherapy and hyperfractionation chemoradiotherapy in two groups. Am J Clin Oncol 2002;25:442446.

    • Search Google Scholar
    • Export Citation
  • 213.

    Yau T, Lo CY, Epstein RJ. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease treated by combination of surgery and radiotherapy. Ann Surg Oncol 2008;15:25002505.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1041 644 65
PDF Downloads 195 134 9
EPUB Downloads 0 0 0